These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23703836)

  • 1. Finding the balance: the role of S-adenosylmethionine and phosphatidylcholine metabolism in development of nonalcoholic fatty liver disease.
    Jacobs RL; van der Veen JN; Vance DE
    Hepatology; 2013 Oct; 58(4):1207-9. PubMed ID: 23703836
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulating interferon antiviral activity: a role for epidermal growth factor receptor.
    Schoggins JW
    Hepatology; 2013 Oct; 58(4):1200-2. PubMed ID: 23703779
    [No Abstract]   [Full Text] [Related]  

  • 3. Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha.
    Lupberger J; Duong FH; Fofana I; Zona L; Xiao F; Thumann C; Durand SC; Pessaux P; Zeisel MB; Heim MH; Baumert TF
    Hepatology; 2013 Oct; 58(4):1225-35. PubMed ID: 23519785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the antiviral activity of ribavirin against hepatitis C virus in cell culture.
    Felmlee DJ; Xiao F; Baumert TF
    Hepatology; 2013 Oct; 58(4):1203-6. PubMed ID: 23703706
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatitis C virus double-stranded RNA is the predominant form in human liver and in interferon-treated cells.
    Klepper A; Eng FJ; Doyle EH; El-Shamy A; Rahman AH; Fiel MI; Avino GC; Lee M; Ye F; Roayaie S; Bansal MB; MacDonald MR; Schiano TD; Branch AD
    Hepatology; 2017 Aug; 66(2):357-370. PubMed ID: 27642141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes.
    Gal-Tanamy M; Bachmetov L; Ravid A; Koren R; Erman A; Tur-Kaspa R; Zemel R
    Hepatology; 2011 Nov; 54(5):1570-9. PubMed ID: 21793032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin a, on interferon-induced antiviral protein in human hepatocyte cells.
    Hirano K; Ichikawa T; Nakao K; Matsumoto A; Miyaaki H; Shibata H; Eguchi S; Takatsuki M; Ikeda M; Yamasaki H; Kato N; Kanematsu T; Ishii N; Eguchi K
    Liver Transpl; 2008 Mar; 14(3):292-8. PubMed ID: 18306331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amino acid substitutions of hepatitis C virus core protein are not associated with intracellular antiviral response to interferon-α in vitro.
    Ikeda F; Dansako H; Nishimura G; Mori K; Kawai Y; Ariumi Y; Miyake Y; Takaki A; Nouso K; Iwasaki Y; Ikeda M; Kato N; Yamamoto K
    Liver Int; 2010 Oct; 30(9):1324-31. PubMed ID: 20602680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic modeling of pegylated-interferon alfa.
    Dimova RB; Talal AH
    J Hepatol; 2010 Sep; 53(3):418-20. PubMed ID: 20561707
    [No Abstract]   [Full Text] [Related]  

  • 10. HM10660A, a long-acting hIFN-α-2b, is a potent candidate for the treatment of hepatitis C through an enhanced biological half-life.
    Bae S; Sim T; Lim C; Kim D; Lee J; Park Y; Jung S; Choi I; Kwon S; Oh KT
    Int J Pharm; 2017 Dec; 534(1-2):89-96. PubMed ID: 28982547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics.
    Lanford RE; Guerra B; Lee H; Chavez D; Brasky KM; Bigger CB
    Hepatology; 2006 May; 43(5):961-72. PubMed ID: 16628626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated IFN-α suppresses hepatitis C virus by promoting the DAPK-mTOR pathway.
    Liu WL; Yang HC; Hsu CS; Wang CC; Wang TS; Kao JH; Chen DS
    Proc Natl Acad Sci U S A; 2016 Dec; 113(51):14799-14804. PubMed ID: 27930338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interfering with interferon: re-igniting the debate on calcineurin inhibitor choice and antiviral therapy for hepatitis C virus recurrence.
    Watashi K; Metselaar HJ; van der Laan LJ
    Liver Transpl; 2008 Mar; 14(3):265-7. PubMed ID: 18306373
    [No Abstract]   [Full Text] [Related]  

  • 14. Secreted Interferon-Inducible Factors Restrict Hepatitis B and C Virus Entry In Vitro.
    Xia Y; Cheng X; Blossey CK; Wisskirchen K; Esser K; Protzer U
    J Immunol Res; 2017; 2017():4828936. PubMed ID: 28367455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus resistance to antiviral therapy.
    Pawlotsky JM
    Hepatology; 2000 Nov; 32(5):889-96. PubMed ID: 11050035
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel interferons for treatment of hepatitis C virus.
    Clark V; Nelson DR
    Clin Liver Dis; 2009 Aug; 13(3):351-63. PubMed ID: 19628153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitro.
    Duong FH; Christen V; Filipowicz M; Heim MH
    Hepatology; 2006 Apr; 43(4):796-806. PubMed ID: 16557551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the nonstructural protein 4B of hepatitis C virus as a factor that inhibits the antiviral activity of interferon-alpha.
    Xu J; Liu S; Xu Y; Tien P; Gao G
    Virus Res; 2009 Apr; 141(1):55-62. PubMed ID: 19185598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea as an inhibitor of hepatitis C virus RNA replication.
    Nozaki A; Morimoto M; Kondo M; Oshima T; Numata K; Fujisawa S; Kaneko T; Miyajima E; Morita S; Mori K; Ikeda M; Kato N; Tanaka K
    Arch Virol; 2010 Apr; 155(4):601-5. PubMed ID: 20204428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal dosage of ribavirin.
    Mangia A; Andriulli A
    Hepatology; 2010 Sep; 52(3):1174. PubMed ID: 20812365
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.